title: Population-based survival analyses of central nervous system tumors from 1994 to 2008. An up-dated study in the temozolomide-era.
abstract: The present population-based study describes the survival of malignant central nervous system (CNS) tumors diagnosed during 15 years. Also, we obtained individual data regarding the use of temozolomide to analyze the impact of this drug on the survival of patients diagnosed with glioblastoma. From 1994 to 2008, a total of 679 incident cases of primary CNS tumors were reported by the Girona Cancer Registry after excluding 39 cases diagnosed by death certificate only. Number of cases and the corresponding proportion for each CNS histological subtype in the study population were: 25 oligodendroglial and oligoastrocytics (3.7%), 22 ependymal tumors (3.2%), 24 embryonal (3.5%), 372 astrocytic (54.8%), 1 choroid plexus (0.1%) and 235 without histological confirmation (34.6%). Observed survival after 5 years since diagnosis for the histological subtype were: 58.8%; 47.5%; 37.0%; 14.5% and 6.5%, respectively (p<0.001). Survival of patients diagnosed with glioblastoma according to temozolomide treatment (yes/no) was 60.8% vs. 13.6% and 5.9% vs. 2.5% after 1 and 5 years since diagnosis, respectively. Short-term survival was higher for patients diagnosed with glioblastoma and treated with temozolomide than patients not treated with temozolomide.
authors.affiliation: Radiation Oncology Service, Catalan Institute of Oncology, Girona, Spain; Girona Biomedical Research Institute (IdiBGi), Girona, Spain. Electronic address: rfuentes@iconcologia.net.
authors.forename: Rafael
authors.initials: R
authors.lastname: Fuentes-Raspall
authors.affiliation: Epidemiology Unit and Girona Cancer Registry (UERCG), Catalan Institute of Oncology, Girona, Spain; Girona Biomedical Research Institute (IdiBGi), Girona, Spain; Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Spain.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Puig-Vives
authors.affiliation: Pharmacy Service, Catalan Institute of Oncology, Girona, Spain.
authors.forename: Silvia
authors.initials: S
authors.lastname: Guerra-Prio
authors.affiliation: Pathology Service, Hospital Universitari Doctor Josep Trueta, Girona, Spain.
authors.forename: Ferran
authors.initials: F
authors.lastname: Perez-Bueno
authors.affiliation: Epidemiology Unit and Girona Cancer Registry (UERCG), Catalan Institute of Oncology, Girona, Spain; Girona Biomedical Research Institute (IdiBGi), Girona, Spain; Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Marcos-Gragera
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013030:Spain / Q000453:epidemiology; D016019:Survival Analysis; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
keywords: Population-based study; Primary brain tumors; Survival; Temozolomide